X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate IMG-7289 (bomedemstat), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition January 11, 2023
Details:
Phase 2 study of IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF) conducted at the Department of Medicine, Queen Mary Hospital.
Lead Product(s): Bomedemstat,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia.
Lead Product(s): Bomedemstat,Venetoclax
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition November 21, 2022
Details:
IMG-7289 (bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
As of the data cutoff of, IMG-7289 (bomedemstat) demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
IMG-7289 (bomedemstat), an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
A combination of IMG-7289 (bomedemstat), in solid tumors enhances their immunogenicity, and atezolizumab, a checkpoint inhibitor, represents in lung cancer treatment, may provide long-term disease management possibilities for patients with small cell lung cancer.
Lead Product(s): Bomedemstat,Atezolizumab
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Washington University School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
IMG-7289 (bomedemstat) is an orally available LSD1 inhibitor, reduced elevated peripheral cell counts, spleen size, inflammatory cytokines, mutant allele frequencies, and marrow fibrosis.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
IMG-7289 (Bomedemstat), demonstrated durable clinical improvement in patients with ET who failed at least one standard therapy (usually hydroxyurea) and it is generally well-tolerated.
Lead Product(s): Bomedemstat
Therapeutic Area: Oncology Product Name: IMG-7289
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
